CD33 and neoplasm: By targeting tumor-associated antigens, such as CD33 or EGFR, while simultaneously inhibiting checkpoint pathways like PD-1/PD-L1 or CTLA-4, CiTEs overcome immune suppression within the tumor microenvironment and restore T-cell activation.